Company: ZLAB
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0001628280-25-018384
Chunk: 73

Company: Zai Lab Ltd
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 73
---
 for awards granted in prior years and vesting in the covered fiscal year |     |                     |   -441,564 |     |   |    -42,600 |     |   |   -604,363 |     |   |    -71,684 |     |   |  1,554,285 |
| Forfeitures during covered fiscal year equal to prior year-end fair value                                                                                       |     |                     |          — |     |   |   -419,154 |     |   |          — |     |   |          — |     |   |          — |
| Incremental fair value resulting from modifications of stock options and RSUs in the covered fiscal year not reflected in the other rows                        |     |                     |          — |     |   |    449,989 |     |   |          — |     |   |          — |     |   |          — |
| Compensation Actually Paid (as calculated)                                                                                                                      |     |                     |  4,795,966 |     |   |  2,298,340 |     |   |  3,550,025 |     |   | -4,953,702 |     |   | 22,814,071 |

*Adjustments are calculated using the same methodology as used in the Company’s financial statements under generally accepted accounting principles and, for awards subject to performance-based vesting conditions, based on the probable outcome of such performance-based vesting conditions as of the last day of the applicable fiscal year.

(4) TSR is determined based on the value of an initial fixed investment of $100, and the reinvestment of all dividends are assumed. The peer group consists of the NASDAQ Biotechnology Index.

(5) Revenue growthis calculated as follows: (total revenues from our audited annual consolidated statements of operations for the current year - total revenues from our audited annual consolidated statements of operations for the prior year) / total revenues from our audited annual consolidated statements of operations for the prior year.

### Financial Performance Measures
The most important financial performance measures identified by the Company as linking executive compensation actually paid to our named executive officers, for the most recently completed fiscal year, to our performance are as follows:

• Revenue growth

• Product revenues

• Commercial profitability

• Year-end cash and cash equivalents

#### Pay Versus Performance: Graphical Description
The illustrations below provide a graphical description of CAP (as calculated in accordance with the SEC rules) compared to: (1)